Your Digital Twin - UnlearnAI

On this episode is biophysicist, machine learning researcher, and CEO of UnlearnAI Dr. Charles Fisher. He and the team at Unlearn have the goal to build the entire biomedical machine learning stack, from scratch. Their strategy is that with a fit-for-purpose biomedical machine learning infrastructure and novel deep learning techniques, along with enough data about patients, that they can generate synthetic versions of actual patients, entirely in the data, with the goal to make them “computationally indistinguishable” from real patients.


Using AI Digital Twins for Drug Testing


Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials


Unlearn.AI Closes On $12M To Improve Clinical Trials

The Unlearn platform processes historical clinical trial datasets from thousands of patients to build the disease-specific machine-learning models used to create what is called “Digital Twins” and...
“Unlearn’s pioneering use of Digital Twins will limit the number of patients that need to go on placebo while also reducing overall trial enrollment time."
Dr. Charles Fisher, CEO of Unlearn AI, discusses creating digital clones by using artificial intelligence for use in clinical drug trials.